Overview
Applied Therapeutics
?
Les Funtleyder
See more contacts
Scientific Research and Development Services
,
Pharmaceutical and Medicine Manufacturing
,
Professional, Scientific, and Technical Services
,
Commercial physical research
,
Medical research, commercial
See All Industries Pharmaceutical preparations
See Fewer Industries
See All Industries Pharmaceutical preparations
See Fewer Industries
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
$455,000
Actual
-95.45%
$86
DEC
?
?
NASDAQ:APLT
Contacts
Get in Touch with 5 Principals* and 26 Contacts
-
Les FuntleyderChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$455,000
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$84 | -$55 | -$78 |
| Net Investing Cash | $ | $14 | $13 |
| Net Financing Cash | $114 | $75 | $28 |
| Net Change in Cash | $30 | $33 | -$37 |
| Cash at Beginning of Period | $50 | $17 | $54 |
| Cash at End of Period | $79 | $50 | $17 |
| Capital Expenditure | $ | $ | $ |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $79 | $50 | $17 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $4 | $4 | $21 |
| Asset Summary | |||
| Total Current Assets | $84 | $54 | $37 |
| Tangible Fixed Assets | $3 | $0 | $1 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $87 | $55 | $38 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $4 | $2 | $5 |
| Short-Term Debt | $ | $0 | $1 |
| Other Current Liabilities | $23 | $69 | $28 |
| Liability Summary | |||
| Total Current Liabilities | $27 | $71 | $33 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $1 | $0 |
| Total Liabilities | $30 | $72 | $34 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$574 | -$469 | -$349 |
| Equity Summary | |||
| Total Equity | $57 | -$17 | $4 |
| Shares Outstanding | 137,228,741 | 84,869,832 | 48,063,358 |